HC Wainwright Reaffirms Buy Rating for Evaxion Biotech A/S (NASDAQ:EVAX)

Evaxion Biotech A/S (NASDAQ:EVAX)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research note issued on Friday, Benzinga reports. They currently have a $14.00 price objective on the stock. HC Wainwright’s price target would suggest a potential upside of 368.23% from the stock’s current price.

Evaxion Biotech A/S Price Performance

Shares of EVAX opened at $2.99 on Friday. Evaxion Biotech A/S has a 1-year low of $2.26 and a 1-year high of $13.61. The firm has a fifty day simple moving average of $3.00 and a two-hundred day simple moving average of $3.31. The company has a current ratio of 2.80, a quick ratio of 2.80 and a debt-to-equity ratio of 7.99. The firm has a market cap of $16.18 million, a PE ratio of -0.69 and a beta of -0.27.

Evaxion Biotech A/S (NASDAQ:EVAX) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.14). The firm had revenue of $0.15 million for the quarter, compared to analysts’ expectations of $0.10 million. During the same period last year, the firm posted ($2.10) earnings per share. On average, equities analysts anticipate that Evaxion Biotech A/S will post -0.24 EPS for the current year.

Institutional Investors Weigh In On Evaxion Biotech A/S

A number of hedge funds have recently modified their holdings of EVAX. LM Advisors LLC bought a new stake in shares of Evaxion Biotech A/S during the 4th quarter valued at $231,000. Invst LLC bought a new stake in shares of Evaxion Biotech A/S during the 2nd quarter valued at $156,000. Finally, Armistice Capital LLC boosted its holdings in Evaxion Biotech A/S by 6.8% in the 2nd quarter. Armistice Capital LLC now owns 392,000 shares of the company’s stock worth $1,137,000 after buying an additional 25,000 shares during the period. Institutional investors own 11.04% of the company’s stock.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers.